In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

@article{Reese2013InVI,
  title={In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor},
  author={Melinda J. Reese and Paul M. Savina and Grant T. Generaux and Helen Tracey and Joan E. Humphreys and Eri Kanaoka and Lindsey O. Webster and Kelly A. Harmon and James D. Clarke and Joseph W. Polli},
  journal={Drug Metabolism and Disposition},
  year={2013},
  volume={41},
  pages={353 - 361}
}
Dolutegravir (DTG; S/GSK1349572) is a potent HIV-1 integrase inhibitor with a distinct resistance profile and a once-daily dose regimen that does not require pharmacokinetic boosting. This work investigated the in vitro drug transport and metabolism of DTG and assessed the potential for clinical drug-drug interactions. DTG is a substrate for the efflux transporters P-glycoprotein (Pgp) and human breast cancer resistance protein (BCRP). Its high intrinsic membrane permeability limits the impact… 

Tables from this paper

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

In vitro results with CYPs and transporters were correlated with the available clinical DDIs using basic models and mechanistic static models, and zanubrutinib is not likely to be involved in transporter‐mediated DDIs.

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam

  • M. ReeseG. Bowers J. Polli
  • Biology, Medicine
    Xenobiotica; the fate of foreign compounds in biological systems
  • 2016
Based on regulatory guidelines and quantitative extrapolations, CAB has a low propensity to cause clinically significant drug interactions, except for coadministration with OAT1 or OAT3 substrates.

Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation

ABSTRACT Raltegravir (RAL) is a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor approved to treat HIV infection in adults in combination with other antiretrovirals. The potential of

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Consensus is lacking on the choice of the most robust and specific human BCRP substrates and inhibitors and optimal study design, and a path forward is proposed based on a comprehensive analysis of available data.

The role of glucuronidation in drug resistance.

Pharmacokinetic drug interactions of integrase strand transfer inhibitors

Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters

In vitro data suggest that delamanid is unlikely to have clinically relevant interactions with drugs for which absorption and disposition are mediated by this group of transporters.

ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors

The aims of the review are to cover transporter interaction profile of substrates and inhibitors that can be utilized to test interaction of drug candidates with ABCG2, to highlight main characteristics of in vitro testing and to describe the structural basis of the broad substrate specificity of the protein.

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions

The pharmacokinetic profile of doravirine supports its use in diverse populations living with HIV-1 and allows co-administration with various antiretroviral agents and treatments for commonly occurring co-morbidities.

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

The pharmacokinetics and pharmacodynamics of the integrase strand transfer inhibitor agents are summarized and compared, and specific pharmacokinetic considerations for persons with hepatic impairment, renal dysfunction, pregnancy, and co-infections are described.
...

References

SHOWING 1-10 OF 52 REFERENCES

Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.

The new antiretrovirals bear the potential to modulate expression and function of several ABC transporters, with elvitegravir revealing the highest interaction potential.

IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES

It is recommended that digoxin be considered as the standard in vitro probe to investigate the inhibition profiles of new drug candidates and shows that it may not be necessary to generate IC50 values with multiple probe substrates for Pgp as is currently done for cytochrome P450 3A4.

Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions

Many of the paradoxical drug interactions (or lack thereof) with the PIs are metabolismrather than transporter-based and are due to induction of CYP2B6 and 2C enzymes.

Interaction Potential of Etravirine with Drug Transporters Assessed In Vitro

It is demonstrated that etravirine has the potential for drug-drug interactions by modulation of expression and function of several ABC transporters.

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

The data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation, which is similar to that demonstrated in rats.

Membrane transporters in drug development

Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions, as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.

Biotransformation of the Antiretroviral Drug Etravirine: Metabolite Identification, Reaction Phenotyping, and Characterization of Autoinduction of Cytochrome P450-Dependent Metabolism

Etravirine and ETR metabolites are substrates of CYP2C19, CYP3A4, CYp2C9, UGT1A3, and UGT 1A8 and that ETR is a PXR-dependent modulator of CYp3A 4 mRNA levels and the presence of the pregnane X receptor antagonist sulforaphane blocked the ETR-mediated increase in CYP 3A4 mRNA expression.

Rational use of in vitro P-glycoprotein assays in drug discovery.

The efflux assay is more reliable at low/moderate P(app) and is the method of choice for evaluating drug candidates despite low throughput and reliance on liquid chromatography with tandem mass spectrometry.

A regulatory viewpoint on transporter-based drug interactions.

A regulatory viewpoint on transporters and their potential role in drug-drug interactions is provided and criteria that may warrant conduct of in vivo P-gp-mediated drug interaction studies based on in vitro assessment are explained.
...